# Biotinylated SARS-CoV-2 Spike RBD Protein (S477N, E484K), His,Avitag™ (MALS verified)

Catalog # SPD-C82Ef



### **Synonym**

Spike,S protein RBD,Spike glycoprotein Receptor-binding domain,S glycoprotein RBD,Spike protein RBD

### Source

Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag (SPD-C82Ef) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1 (S477N, E484K)). The mutations (S477N, E484K) were identified in the SARS-CoV-2 variants which emerged in Europe (known as B.1.620).

Predicted N-terminus: Arg 319

### **Molecular Characterization**

Spike RBD (Arg 319 - Lys 537)
QHD43416.1

Poly-his

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag<sup>TM</sup>)

The protein has a calculated MW of 28.2 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

### Labeling

Biotinylation of this product is performed using Avitag<sup>TM</sup> technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

#### **Protein Ratio**

Passed as determined by the HABA assay / binding ELISA.

## Endotoxin

Less than 1.0 EU per µg by the LAL method.

### **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

#### **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


### **SDS-PAGE**



Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

# **Bioactivity-ELISA**

### **SEC-MALS**



The purity of Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag (Cat. No. SPD-C82Ef) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.


Report

# Biotinylated SARS-CoV-2 Spike RBD Protein (S477N, E484K), His,Avitag™ (MALS verified)

Catalog # SPD-C82Ef




Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag ELISA  $0.1~\mu g$  of Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag per well



Immobilized Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag (Cat. No. SPD-C82Ef) at 1  $\mu$ g/mL (100  $\mu$ L/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5  $\mu$ g/well) plate can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-2  $\mu$ g/mL (QC tested).

Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag ELISA 0.1  $\mu$ g of Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag per well



Immobilized Biotinylated SARS-CoV-2 Spike RBD (S477N, E484K), His,Avitag (Cat. No. SPD-C82Ef) at 1  $\mu$ g/mL (100  $\mu$ L/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5  $\mu$ g/well) plate can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.1-2 ng/mL (Routinely tested).

# Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

### **Clinical and Translational Updates**

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.